Copernicus Therapeutics, Inc. (CTI) is a clinical-stage biopharmaceutical company specializing in precision medicine and gene therapy. Through its proprietary, non-viral, nucleic acid nanoparticle platform, the company is able to achieve gene transfer in several tissues without the immune response and limited treatment window of adeno-associated viruses.